Member Info for Obsisian

If you're taking your lead from the Singer note...

When is a professional report anything but? This critique unpacks the gaping analytical chasm between the high-gloss optimism of Singer Capital Markets and the grounded, sceptical rigour of Lemming Investor. From inflated valuations and lazy peer comparisons to missing risk analysis and fiscal blind spots, this is a forensic look at what happens when investor trust is built on sand. Essential reading for anyone who still believes “professional” means “credible.”

https://lemminginvestor.substack.com/p/solvonis-therapeutics-plc

https://psychological4investors.substack.com/p/solvonis-therapeutics-plc

Beware the season of influencer-driven sentiment: masked sceptics or promoters—like Belgrano—tend to prey on AIM's opacity and thin liquidity, manipulating emotional triggers to spur buying or selling. As of now, INSG has firmer fundamentals acknowledging volatility, while SBTX remains best treated as speculative pending concrete data.

He’s playing on mental frailty—exploiting doubt in the hope some will capitulate and follow him into INSG, where he chased the price into the high 30s. It now languishes at 26p. Clearly, many of you see through it—the silence in the ‘likes’ says more than any reply ever could.

https://psychological4investors.substack.com/p/belgranos-balancing-act-between-oracle

Ashman has lost it. https://open.substack.com/pub/jl1995/p/skinbiotherapeutics-plc?r=5eb7sb&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

It's a mirage. https://open.substack.com/pub/lemminginvestor/p/skinbiotherapeutics-plc-e0b?r=5eb7sb&utm_campaign=comment-list-share-cta&utm_medium=web&comments=true&commentId=129819652

You may find the research provides specific detail noteworthy.

Extract to open source report - not entirely WITHOUT influence because it does appear to be commissioned by OPTI

The Double-Edged Sword of Wegovy — A Closer Look at the Health Impact and Market Ripple Effects

Wegovy, the high-profile GLP-1 receptor agonist marketed as a weight loss breakthrough, has become a symbol of both therapeutic promise and medical controversy. Developed to address the obesity epidemic with scientific rigour, its clinical efficacy is striking. In trials, patients lost an average of nearly 15% of their body weight over 68 weeks — a figure that has reshaped the landscape of metabolic intervention. But this success story carries a sharp counterpoint: a side effect profile that is both significant and consequential.

Based on information from reliable sources such as Wegovy Side Effects | Wegovy® (semaglutide) Injection 2.4 mg and Wegovy Side Effects: Common, Mild, Serious, and Long-Term, the following side effects have been documented.

https://tinyurl.com/4cauj977

During Elric's interview, Ashman made it abundantly clear that the market would have visibility on Croda's figures to date. Since then, we’ve witnessed a flurry of substantial buys — yet the share price has barely flinched. One doesn’t need a magnifying glass to see what's going on: Marex and Singer appear to be quietly filling orders in anticipation of forthcoming news.

Crucially, there remains a conspicuous shortfall of 21 million shares from the £4.2m raise. It's difficult to believe all of these would escape TR1 disclosures. It feels increasingly evident that the share price has been deliberately walked down — and Ashman is either complicit or dangerously naïve.

One has to ask: what exactly is Ashman waiting for? There’s no IMC scheduled, and we’re approaching month-end. Could it be that Marex and Singer are stalling, reluctant to stoke market expectations before they’ve completed their accumulation? Something here does not add up.